Adalimumab biosimilar - Pfizer

Drug Profile

Adalimumab biosimilar - Pfizer

Alternative Names: PF-06410293

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 01 May 2016 Pfizer completes a phase I comparative pharmacokinetics trial in healthy subjects in USA (NCT02572245)
  • 01 Mar 2015 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT02237729)
  • 27 Oct 2014 Phase-III clinical trials in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Germany, Hungary, Estonia, Czech Republic (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top